Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Dear Colleague,
We are pleased to announce that Grand Challenge 3 (GC3) is planned to
open at the start of September, with the first stage closing ~September
25, the second stage closing at the start of December, and an in-person
workshop in La Jolla Feb 21-22, 2018.
With ~200 noncovalent ligands measured against Cathepsin S, ~80 ligands
all measured against three kinases, and two congeneric series of ~20
kinase ligands apiece, each containing an activity cliff, this will be
the "grandest" challenge to date!
The Cathepsin S inhibitors are part of a larger collection of ligands,
which we will continue to draw from in subsequent challenges. (Many
thanks to Janssen for this expansive dataset.)
We will send further updates as the opening approaches!
Best regards,
D3R Team